Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain

Graus, F. ; Bruna, J. ; Pardo, J. ; Escudero, D. ; Vilas, D. ; Barceló, I. ; Brell, M. ; Pascual, C. ; Crespo, J. A. ; Erro, E. ; García-Romero, J. C. ; Estela, J. ; Martino, J. ; García-Castaño, A. ; Mata, E. ; Lema, M. ; Gelabert, M. ; Fuentes, R. ; Pérez, P. ; Manzano, A. ; Aguas, J. (Universidad de Zaragoza) ; Belenguer, A. ; Simón, A. ; Henríquez, I. ; Murcia, M. ; Vivanco, R. ; Rojas-Marcos, I. ; Muñoz-Carmona, D. ; Navas, I. ; De Andrés, P. ; Mas, G. ; Gil, M. ; Verger, E.

Resumen: BackgroundTo assess management patterns and outcome in patients with glioblastoma multiforme (GBM) treated during 2008-2010 in Spain. MethodsRetrospective analysis of clinical, therapeutic, and survival data collected through filled questionnaires from patients with histologically confirmed GBM diagnosed in 19 Spanish hospitals.ResultsWe identified 834 patients (23% aged >70 years). Surgical resection was achieved in 66% of patients, although the extent of surgery was confirmed by postoperative MRI in only 41%. There were major postoperative complications in 14% of patients, and age was the only independent predictor (Odds ratio OR], 1.03; 95% confidence interval CI], 1.01-1.05; P =. 006). After surgery, 57% received radiotherapy (RT) with concomitant and adjuvant temozolomide, 21% received other regimens, and 22% were not further treated. In patients treated with surgical resection, RT, and chemotherapy (n = 396), initiation of RT =42 days was associated with longer progression-free survival (hazard ratio HR], 0.8; 95% CI, 0.64-0.99; P =. 042) but not with overall survival (HR, 0.79; 95% CI, 0.62-1.00; P =. 055). Only 32% of patients older than 70 years received RT with concomitant and adjuvant temozolomide. The median survival in this group was 10.8 months (95% CI, 6.8-14.9 months), compared with 17.0 months (95% CI, 15.5-18.4 months; P =. 034) among younger patients with GBM treated with the same regimen.ConclusionsIn a community setting, 57% of all patients with GBM and only 32% of older patients received RT with concomitant and adjuvant temozolomide. In patients with surgical resection who were eligible for chemoradiation, initiation of RT =42 days was associated with better progression-free survival.

Idioma: Inglés

DOI: 10.1093/neuonc/not013

Año: 2013

Publicado en: NEURO-ONCOLOGY 15, 6 (2013), 797-805
ISSN: 1522-8517

Factor impacto JCR: 5.286 (2013)

Categ. JCR: ONCOLOGY rank: 30 / 203 = 0.148 (2013) - Q1 - T1
Categ. JCR: CLINICAL NEUROLOGY rank: 18 / 191 = 0.094 (2013) - Q1 - T1

Tipo y forma: Article (Published version)

Área (Departamento): Área Cirugía (Dpto. Cirugía,Ginecol.Obstetr.)